Oncology Peer Review On-The-Go: Barriers to Pancreatic Cancer Clinical Trial Enrollment

Podcast

The latest installment of “Oncology Peer Review On-The-Go” dissects original research published in the journal ONCOLOGY regarding potential barriers to clinical trial enrollment for patients with pancreatic cancer.

This episode of "Oncology Peer Review On-The-Go" examines an article published in the October issue of the journal ONCOLOGY, titled “Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Who Are Eligible for Early-Phase Clinical Trials.”

The piece was written by Rachael Galvin, DO, MPH, Christine Chung, DO, Ella Achenbach, Oliwier Dziadkowiec, PhD, and Shiraj Sen, MD, PhD, and focuses on what keeps patients with this aggressive form of pancreatic cancer from pursuing enrollment in clinical trials. For a summary of the article, CancerNetwork spoke with Galvin, lead author of the study who is from the Swedish Medical Center in Englewood, Colorado.

For the article’s response perspective, CancerNetwork spoke with Michael Lee, MD, from The University of Texas MD Anderson Cancer Center in Houston. Lee discussed his perspective piece published on CancerNetwork titled “Barriers to Pancreatic Cancer Clinical Trials Enrollment.” The piece examines Galvin’s work and clinical trial enrollment for the disease as a whole.

Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
Related Content